The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-cyano-N-[4-({[8-methyl-2-(methylamino)quinazolin-4-yl]amino}methyl)phenyl]benzamide trifluoroacetate salt ID: ALA3928449
PubChem CID: 134140848
Max Phase: Preclinical
Molecular Formula: C27H23F3N6O3
Molecular Weight: 422.49
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: CNc1nc(NCc2ccc(NC(=O)c3ccc(C#N)cc3)cc2)c2cccc(C)c2n1.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C25H22N6O.C2HF3O2/c1-16-4-3-5-21-22(16)30-25(27-2)31-23(21)28-15-18-8-12-20(13-9-18)29-24(32)19-10-6-17(14-26)7-11-19;3-2(4,5)1(6)7/h3-13H,15H2,1-2H3,(H,29,32)(H2,27,28,30,31);(H,6,7)
Standard InChI Key: ZNENUUSDVKLJOW-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 41 0 0 0 0 0 0 0 0999 V2000
43.7419 -14.2854 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
43.0369 -13.8768 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
43.7419 -15.1026 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
44.4499 -13.8774 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
45.1573 -14.2866 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
44.4506 -13.0602 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
45.1519 -13.4630 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
41.5527 -14.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.5527 -13.8611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.8395 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.8395 -12.6312 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.5527 -12.2185 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.2618 -12.6312 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.2618 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
42.2618 -15.0952 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
40.8395 -15.0952 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
40.1304 -14.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.4213 -15.0952 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.7081 -14.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
38.7081 -13.8611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
39.4213 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
40.1304 -13.8611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.9949 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
37.2816 -13.8611 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.1544 -12.6312 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
35.8593 -12.2185 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
36.5725 -12.6312 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.5725 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8593 -13.8611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8593 -14.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1544 -15.0952 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4412 -14.6824 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
34.4412 -13.8611 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.1544 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
35.8593 -11.3972 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
36.5725 -10.9886 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
33.7279 -13.4525 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.5527 -11.3972 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
41.5527 -10.5758 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
1 3 1 0
1 4 1 0
4 5 1 0
4 6 1 0
4 7 1 0
8 9 1 0
9 10 1 0
10 11 2 0
11 12 1 0
12 13 2 0
13 14 1 0
9 14 2 0
8 15 2 0
8 16 1 0
17 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 22 1 0
17 22 2 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 30 1 0
30 31 2 0
31 32 1 0
32 33 2 0
33 34 1 0
25 34 2 0
29 34 1 0
35 36 1 0
26 35 1 0
33 37 1 0
24 28 1 0
23 24 1 0
20 23 1 0
16 17 1 0
38 39 3 0
12 38 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 422.49Molecular Weight (Monoisotopic): 422.1855AlogP: 4.72#Rotatable Bonds: 6Polar Surface Area: 102.73Molecular Species: NEUTRALHBA: 6HBD: 3#RO5 Violations: ┄HBA (Lipinski): 7HBD (Lipinski): 3#RO5 Violations (Lipinski): ┄CX Acidic pKa: ┄CX Basic pKa: 6.71CX LogP: 4.83CX LogD: 4.75Aromatic Rings: 4Heavy Atoms: 32QED Weighted: 0.42Np Likeness Score: -1.63
References 1. (2009) Amino-substituted quinazoline derivatives as inhibitors of Beta-catenin/TCF-4 pathway and cancer treatment agents,